BioCryst Initiates Phase 2a Clinical Trial of BCX4161 in Patients with Hereditary Angioedema

By: Benzinga
BioCryst Pharmaceuticals (NASDAQ: BCRX ) today announced that it has dosed the first subject in OPuS-1 (Oral ProphylaxiS-1), a Phase 2a proof of concept clinical trial of orally-administered
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.